FDA022-BB05
- Generic Name
- FDA022-BB05
A Study of FDA022-BB05 in Advanced/Metastatic Solid Tumors
- First Posted Date
- 2024-05-14
- Last Posted Date
- 2024-05-14
- Target Recruit Count
- 150
- Registration Number
- NCT06413615
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath